Stock Analiz

Whitehawk Therapeutics, Inc. WHWK

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.06Market cap $181M
Open the interactive analysis →

Whitehawk Therapeutics, Inc. (WHWK) is a healthcare company listed in the US with a market value of about $181M. In fiscal year 2025 it had revenue of $7M and net income of -$21M, a net margin of -288.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -13% a year, a 5-year average ROIC of -76%.

About Whitehawk Therapeutics

Whitehawk Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $20M in 2018 to $7M in 2025, a decline of about 13.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 175% over three years (dilution for shareholders). It spends 1273% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-40.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-72.5%
Revenue growth (5 yrs, per year)-12.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-397.5%
ROIC (5-yr avg.)-76.3%
Profitable years (of last 10)0
Years paying a dividend1

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$7M$26M$24M$15M$14M$14M$0$20M——
Net income-$21M-$64M-$66M-$61M-$110M-$3M-$23M-$10M-$21M-$17M
Free cash flow-$98M-$61M-$64M-$50M-$22M-$13M-$24M-$6M-$19M-$137814
EPS (diluted)$-0.33$-2.36$-2.44$-2.69$-12.41$-1.76$-9.56$-5.20$-17.27$-411.09
Net margin-288.3%-245.1%-270.0%-397.7%-786.4%-24.8%—-51.6%——
ROIC-83.9%-126.5%-67.6%-39.2%-64.1%——-15.1%-96.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Whitehawk Therapeutics pay a dividend?

Not currently.

Is Whitehawk Therapeutics a good stock to buy?

We do not give buy or sell advice. Whitehawk Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.